ICG vs CANF

For growth investors, Intchains Group Limited (ICG) is the stronger pick with 242.

7% revenue growth year-over-year, versus -9. 3% for Can-Fite BioPharma Ltd. (CANF). Intchains Group Limited (ICG) offers the better valuation at 5. 2x trailing P/E (2. 9x forward), making it the more compelling value choice. Analysts rate Intchains Group Limited (ICG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Can-Fite BioPharma Ltd.

(CANF) delivered a total return of -82. 5%, compared to -83. 5% for Intchains Group Limited (ICG). Over 10 years, the gap is even starker: ICG returned -83. 5% versus CANF's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd.

(CANF) is the lower-risk stock at 0. 88β versus Intchains Group Limited's 1. 84β — meaning ICG is approximately 109% more volatile than CANF relative to the S&P 500. On balance sheet safety, Intchains Group Limited (ICG) carries a lower debt/equity ratio of 0% versus 2% for Can-Fite BioPharma Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Intchains Group Limited (ICG) is pulling ahead at 242.

7% versus -9. 3% for Can-Fite BioPharma Ltd. (CANF). On earnings-per-share growth, the picture is similar: Intchains Group Limited grew EPS 490. 9% year-over-year, compared to 40. 0% for Can-Fite BioPharma Ltd.. Over a 3-year CAGR, CANF leads at -7. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intchains Group Limited (ICG) is the more profitable company, earning 18.

3% net margin versus -1169. 1% for Can-Fite BioPharma Ltd. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ICG leads at 1. 1% versus -1206. 2% for CANF. At the gross margin level — before operating expenses — CANF leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ICG: 203.

0% to $4. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Can-Fite BioPharma Ltd.

(CANF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88)). Intchains Group Limited (ICG) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CANF: -99. 1%, ICG: -83. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ICG (Technology) and CANF (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ICG is a small-cap high-growth stock; CANF is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.